SPDR® S&P Pharmaceuticals ETF (XPH)
| 42.60 Delayed Data As of Jul 01 |  +0.60 / +1.43%Today’s Change | 37.94 Today|||52-Week Range 53.82 | -7.69% Year-to-Date |
Investment Objective
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
Latest XPH News
| 2 ETFs to Watch for Outsized Volume on Dividend and Pharma Jun 28 / Zacks.com - Paid Partner Content |
Performance
| 1 month | +3.39% | 3 years | +2.87% | |
| 3 months | -6.91% | 5 years | +0.62% | |
| 1 year | -17.77% | Since inception | +8.31% |
Data through 07/02/2022
Quote Details
| Previous close | $42.00 |
| Open day’s range | 41.92 – 42.66 |
| Net asset value (NAV) | 42.62 (07/01/2022) |
| Daily volume | 40,040 |
| Average volume (3 months) | 66,884 |
Data as of 3:59pm ET, 07/01/2022
Peer Comparisonvs. Health ETFs
| XPH | Category | |
|---|---|---|
| Performance 5-yr return | +0.62% | +11.31% |
| Expense Gross exp ratio | 0.35% | 1.01% |
| Risk 5 year sharpe ratio | 0.10 | 0.52 |
| Net assets | $186.9M | $1.9B |
| Average market cap | $14.3B | $43.0B |
| Average P/E | 20.8 | 22.2 |
| Dividend / Share | -- | 0.27% |
Competitors
| VHT Vanguard Health Care Index Fund ETF Shar... |
| IEHS iShares Evolved U.S. Healthcare Staples ... |
| FHLC Fidelity MSCI Health Care Index ETF |
Holdings
Top 5 SectorsPortfolio weighting
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
Top 10 HoldingsPortfolio weighting
| VTRS Viatris Inc | 5.80% |
| LLY Eli Lilly and Co | 5.58% |
| MRK Merck | 5.57% |
| BMY Bristol-Myers Squibb | 5.19% |
| RPRX Royalty Pharma PLC | 5.09% |
| CTLT Catalent Inc | 5.08% |
| JNJ Johnson & Johnson | 5.02% |
| OGN Organon & Co | 5.02% |
| PFE Pfizer | 5.00% |
| PRGO Perrigo Company PLC | 5.00% |
